The partnership aims to bring DBLG2, Diabeloop’s newest automated insulin delivery (AID) algorithm, to twiist. DBLG2 picked up FDA clearance last month. Sequel becomes the latest pump maker to adopt the algorithm, with ViCentra planning to roll out its next-generation Kaleido pump with DBLG2. It would mark the first integration of the Diabeloop algorithm into a commercial insulin pump in the U.S. market.

DBLG 1 requires users to only enter body weight and total daily insulin dose before adapting to the user’s needs. Its self-learning module refines parameters over time based on glucose trends and insulin delivery history. This enables responses to the diversity of type 1 diabetes physiologies, specific medical conditions and personal preferences. Users can also choose not to declare meals.